婴儿 RSV 普遍预防的早期经验:事实与期望。

IF 2.3 3区 医学 Q2 CRITICAL CARE MEDICINE
Antoni Soriano-Arandes, Anna Creus-Costa, Aida Perramon-Malavez, Cristina Andrés, Jorgina Vila, Anna Gatell, Maria Piñana, Pepe Serrano, Alejandra González-Sánchez, Ramon Capdevila, Clara Prats, Pere Soler-Palacin, Andrés Antón
{"title":"婴儿 RSV 普遍预防的早期经验:事实与期望。","authors":"Antoni Soriano-Arandes, Anna Creus-Costa, Aida Perramon-Malavez, Cristina Andrés, Jorgina Vila, Anna Gatell, Maria Piñana, Pepe Serrano, Alejandra González-Sánchez, Ramon Capdevila, Clara Prats, Pere Soler-Palacin, Andrés Antón","doi":"10.1055/a-2531-0968","DOIUrl":null,"url":null,"abstract":"<p><p>During the 2023/24 season, nirsevimab significantly reduced the risk of bronchiolitis and confirmed respiratory syncytial virus (RSV) infections in primary care, hospital, and pediatric intensive care unit admissions among infants aged 0 to 11 months, even in a season with a high community RSV burden, particularly for older infants. These findings are very useful for public health authorities to continue to implement immunization campaigns against RSV in the coming seasons. Moreover, universal immunization against RSV represents a transformative step toward reducing the burden of RSV in infants. With promising evidence from recently published studies, the expectations for a reduction of RSV-associated hospitalizations, alongside the improvement of public health outcomes and equitable access to these measures, are high. However, achieving these goals will require addressing challenges related to vaccine uptake, funding, and RSV surveillance to prompt detect resistances due to mutations of the virus. These interventions need to be integrated into public health strategies because they hold the potential to make a significant impact on infant's health worldwide.</p>","PeriodicalId":21727,"journal":{"name":"Seminars in respiratory and critical care medicine","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early Experience on Universal Prophylaxis in Infants against Respiratory Syncytial Virus: Facts and Expectations.\",\"authors\":\"Antoni Soriano-Arandes, Anna Creus-Costa, Aida Perramon-Malavez, Cristina Andrés, Jorgina Vila, Anna Gatell, Maria Piñana, Pepe Serrano, Alejandra González-Sánchez, Ramon Capdevila, Clara Prats, Pere Soler-Palacin, Andrés Antón\",\"doi\":\"10.1055/a-2531-0968\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>During the 2023/24 season, nirsevimab significantly reduced the risk of bronchiolitis and confirmed respiratory syncytial virus (RSV) infections in primary care, hospital, and pediatric intensive care unit admissions among infants aged 0 to 11 months, even in a season with a high community RSV burden, particularly for older infants. These findings are very useful for public health authorities to continue to implement immunization campaigns against RSV in the coming seasons. Moreover, universal immunization against RSV represents a transformative step toward reducing the burden of RSV in infants. With promising evidence from recently published studies, the expectations for a reduction of RSV-associated hospitalizations, alongside the improvement of public health outcomes and equitable access to these measures, are high. However, achieving these goals will require addressing challenges related to vaccine uptake, funding, and RSV surveillance to prompt detect resistances due to mutations of the virus. These interventions need to be integrated into public health strategies because they hold the potential to make a significant impact on infant's health worldwide.</p>\",\"PeriodicalId\":21727,\"journal\":{\"name\":\"Seminars in respiratory and critical care medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in respiratory and critical care medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2531-0968\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in respiratory and critical care medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2531-0968","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

摘要

在2023-2024年季节,即使在社区RSV负担较高的季节,特别是对于年龄较大的婴儿,nirsevimab也显着降低了0至11个月婴儿的初级保健、医院和儿科重症监护病房入院的毛细支气管炎和确诊RSV感染的风险。这些发现对公共卫生当局在未来季节继续实施针对呼吸道合胞病毒的免疫运动非常有用。此外,针对呼吸道合胞病毒的普遍免疫是朝着减少婴儿呼吸道合胞病毒负担迈出的变革性一步。鉴于最近发表的研究提供了令人鼓舞的证据,人们对减少与rsv相关的住院率,以及改善公共卫生结果和公平获得这些措施的期望很高。然而,实现这些目标将需要解决与疫苗接种、资金和RSV监测有关的挑战,以便及时发现由于病毒突变引起的耐药性。这些干预措施需要纳入公共卫生战略,因为它们有可能对全世界婴儿的健康产生重大影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Early Experience on Universal Prophylaxis in Infants against Respiratory Syncytial Virus: Facts and Expectations.

During the 2023/24 season, nirsevimab significantly reduced the risk of bronchiolitis and confirmed respiratory syncytial virus (RSV) infections in primary care, hospital, and pediatric intensive care unit admissions among infants aged 0 to 11 months, even in a season with a high community RSV burden, particularly for older infants. These findings are very useful for public health authorities to continue to implement immunization campaigns against RSV in the coming seasons. Moreover, universal immunization against RSV represents a transformative step toward reducing the burden of RSV in infants. With promising evidence from recently published studies, the expectations for a reduction of RSV-associated hospitalizations, alongside the improvement of public health outcomes and equitable access to these measures, are high. However, achieving these goals will require addressing challenges related to vaccine uptake, funding, and RSV surveillance to prompt detect resistances due to mutations of the virus. These interventions need to be integrated into public health strategies because they hold the potential to make a significant impact on infant's health worldwide.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.10
自引率
0.00%
发文量
87
审稿时长
6-12 weeks
期刊介绍: The journal focuses on new diagnostic and therapeutic procedures, laboratory studies, genetic breakthroughs, pathology, clinical features and management as related to such areas as asthma and other lung diseases, critical care management, cystic fibrosis, lung and heart transplantation, pulmonary pathogens, and pleural disease as well as many other related disorders.The journal focuses on new diagnostic and therapeutic procedures, laboratory studies, genetic breakthroughs, pathology, clinical features and management as related to such areas as asthma and other lung diseases, critical care management, cystic fibrosis, lung and heart transplantation, pulmonary pathogens, and pleural disease as well as many other related disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信